vs
Apellis Pharmaceuticals, Inc.（APLS）与EXPRO GROUP HOLDINGS N.V.（XPRO）财务数据对比。点击上方公司名可切换其他公司
EXPRO GROUP HOLDINGS N.V.的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$382.1M vs $199.9M），EXPRO GROUP HOLDINGS N.V.净利率更高（1.5% vs -29.5%，领先31.0%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -12.5%），EXPRO GROUP HOLDINGS N.V.自由现金流更多（$23.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Expro是一家能源服务提供商，总部位于美国得克萨斯州休斯敦，主要为油气等能源领域的客户提供相关技术服务与解决方案，业务覆盖全球多个主要能源产区，助力行业实现高效、安全的开发运营。
APLS vs XPRO — 直观对比
营收规模更大
XPRO
是对方的1.9倍
$199.9M
营收增速更快
APLS
高出6.6%
-12.5%
净利率更高
XPRO
高出31.0%
-29.5%
自由现金流更多
XPRO
多$37.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $382.1M |
| 净利润 | $-59.0M | $5.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 3.1% |
| 净利率 | -29.5% | 1.5% |
| 营收同比 | -5.9% | -12.5% |
| 净利润同比 | -62.2% | -74.9% |
| 每股收益（稀释后） | $-0.40 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSXPRO
| Q4 25 | $199.9M | $382.1M | ||
| Q3 25 | $458.6M | $411.4M | ||
| Q2 25 | $178.5M | $422.7M | ||
| Q1 25 | $166.8M | $390.9M | ||
| Q4 24 | $212.5M | $436.8M | ||
| Q3 24 | $196.8M | $422.8M | ||
| Q2 24 | $199.7M | $469.6M | ||
| Q1 24 | $172.3M | $383.5M |
净利润APLSXPRO
| Q4 25 | $-59.0M | $5.8M | ||
| Q3 25 | $215.7M | $14.0M | ||
| Q2 25 | $-42.2M | $18.0M | ||
| Q1 25 | $-92.2M | $13.9M | ||
| Q4 24 | $-36.4M | $23.0M | ||
| Q3 24 | $-57.4M | $16.3M | ||
| Q2 24 | $-37.7M | $15.3M | ||
| Q1 24 | $-66.4M | $-2.7M |
营业利润率APLSXPRO
| Q4 25 | -25.6% | 3.1% | ||
| Q3 25 | 48.7% | 6.4% | ||
| Q2 25 | -18.6% | 7.7% | ||
| Q1 25 | -50.0% | 2.6% | ||
| Q4 24 | -12.3% | 7.3% | ||
| Q3 24 | -24.0% | 6.2% | ||
| Q2 24 | -14.7% | 5.9% | ||
| Q1 24 | -36.0% | 2.2% |
净利率APLSXPRO
| Q4 25 | -29.5% | 1.5% | ||
| Q3 25 | 47.0% | 3.4% | ||
| Q2 25 | -23.6% | 4.3% | ||
| Q1 25 | -55.3% | 3.6% | ||
| Q4 24 | -17.1% | 5.3% | ||
| Q3 24 | -29.2% | 3.8% | ||
| Q2 24 | -18.9% | 3.3% | ||
| Q1 24 | -38.5% | -0.7% |
每股收益（稀释后）APLSXPRO
| Q4 25 | $-0.40 | $0.05 | ||
| Q3 25 | $1.67 | $0.12 | ||
| Q2 25 | $-0.33 | $0.16 | ||
| Q1 25 | $-0.74 | $0.12 | ||
| Q4 24 | $-0.30 | $0.20 | ||
| Q3 24 | $-0.46 | $0.14 | ||
| Q2 24 | $-0.30 | $0.13 | ||
| Q1 24 | $-0.54 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $196.1M |
| 总债务越低越好 | — | $79.1M |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.05× |
8季度趋势，按日历期对齐
现金及短期投资APLSXPRO
| Q4 25 | $466.2M | $196.1M | ||
| Q3 25 | $479.2M | $197.9M | ||
| Q2 25 | $370.0M | $206.8M | ||
| Q1 25 | $358.4M | $179.3M | ||
| Q4 24 | $411.3M | $183.0M | ||
| Q3 24 | $396.9M | $165.7M | ||
| Q2 24 | $360.1M | $133.5M | ||
| Q1 24 | $325.9M | $163.2M |
总债务APLSXPRO
| Q4 25 | — | $79.1M | ||
| Q3 25 | — | $99.1M | ||
| Q2 25 | — | $121.1M | ||
| Q1 25 | — | $121.1M | ||
| Q4 24 | — | $121.1M | ||
| Q3 24 | — | $121.1M | ||
| Q2 24 | — | $121.1M | ||
| Q1 24 | $93.1M | $40.0M |
股东权益APLSXPRO
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.5B | ||
| Q4 24 | $228.5M | $1.5B | ||
| Q3 24 | $237.1M | $1.5B | ||
| Q2 24 | $264.3M | $1.5B | ||
| Q1 24 | $266.7M | $1.3B |
总资产APLSXPRO
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $2.3B | ||
| Q2 25 | $821.4M | $2.3B | ||
| Q1 25 | $807.3M | $2.3B | ||
| Q4 24 | $885.1M | $2.3B | ||
| Q3 24 | $901.9M | $2.3B | ||
| Q2 24 | $904.5M | $2.3B | ||
| Q1 24 | $831.9M | $2.0B |
负债/权益比APLSXPRO
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.08× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.08× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | 0.35× | 0.03× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $57.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $23.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 6.1% |
| 资本支出强度资本支出/营收 | 0.1% | 8.9% |
| 现金转化率经营现金流/净利润 | — | 9.89× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $97.8M |
8季度趋势，按日历期对齐
经营现金流APLSXPRO
| Q4 25 | $-14.2M | $57.1M | ||
| Q3 25 | $108.5M | $63.2M | ||
| Q2 25 | $4.4M | $48.4M | ||
| Q1 25 | $-53.4M | $41.5M | ||
| Q4 24 | $19.4M | $97.4M | ||
| Q3 24 | $34.1M | $55.3M | ||
| Q2 24 | $-8.3M | $-13.2M | ||
| Q1 24 | $-133.0M | $29.9M |
自由现金流APLSXPRO
| Q4 25 | $-14.3M | $23.2M | ||
| Q3 25 | $108.3M | $39.0M | ||
| Q2 25 | $4.4M | $27.2M | ||
| Q1 25 | $-53.4M | $8.4M | ||
| Q4 24 | $19.3M | $53.0M | ||
| Q3 24 | — | $23.3M | ||
| Q2 24 | $-8.4M | $-49.5M | ||
| Q1 24 | $-133.3M | $-801.0K |
自由现金流率APLSXPRO
| Q4 25 | -7.1% | 6.1% | ||
| Q3 25 | 23.6% | 9.5% | ||
| Q2 25 | 2.5% | 6.4% | ||
| Q1 25 | -32.0% | 2.1% | ||
| Q4 24 | 9.1% | 12.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | -4.2% | -10.5% | ||
| Q1 24 | -77.3% | -0.2% |
资本支出强度APLSXPRO
| Q4 25 | 0.1% | 8.9% | ||
| Q3 25 | 0.0% | 5.9% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.0% | 8.5% | ||
| Q4 24 | 0.0% | 10.2% | ||
| Q3 24 | 0.0% | 7.6% | ||
| Q2 24 | 0.0% | 7.7% | ||
| Q1 24 | 0.2% | 8.0% |
现金转化率APLSXPRO
| Q4 25 | — | 9.89× | ||
| Q3 25 | 0.50× | 4.52× | ||
| Q2 25 | — | 2.69× | ||
| Q1 25 | — | 2.98× | ||
| Q4 24 | — | 4.23× | ||
| Q3 24 | — | 3.40× | ||
| Q2 24 | — | -0.86× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
XPRO
| NLA | $130.3M | 34% |
| ESSA | $116.3M | 30% |
| MENA | $93.0M | 24% |
| Other | $42.5M | 11% |
